Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 266

1.

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions.

Guigay J, Tahara M, Licitra L, Keilholz U, Friesland S, Witzler P, Mesía R.

Front Oncol. 2019 Aug 21;9:668. doi: 10.3389/fonc.2019.00668. eCollection 2019. Review.

2.

Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study.

Merlano M, Denaro N, Benasso M, Licitra L, Bossi P, Locati L, Vecchio S, Bruzzi P.

Oral Oncol. 2019 Aug 28;97:99-104. doi: 10.1016/j.oraloncology.2019.08.019. [Epub ahead of print]

PMID:
31472438
3.

Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel.

Benasso M, Bonomo P, Buglione M, Ghi MG, Licitra L, Magrini SM, Merlano MC, Presutti L, Ronzino G, Ferrari D.

Tumori. 2019 Aug 28:300891619868289. doi: 10.1177/0300891619868289. [Epub ahead of print]

PMID:
31462160
4.

Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy.

Ferella L, Cavallo A, Miceli R, Iacovelli NA, Giandini T, Pignoli E, Calareso G, Bossi P, Resteghini C, Gravina GL, Nicolai P, Castelnuovo P, Piazza C, Licitra L, Fallai C, Orlandi E.

Tumori. 2019 Aug 27:300891619868006. doi: 10.1177/0300891619868006. [Epub ahead of print]

PMID:
31451102
5.

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.

Haddad R, Guigay J, Keilholz U, Clement PM, Fayette J, de Souza Viana L, Rolland F, Cupissol D, Geoffrois L, Kornek G, Licitra L, Melichar B, Ribaldo Nicolau U, Rauch D, Zanetta-Devauges S, Cohen EEW, Machiels JP, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler T.

Oral Oncol. 2019 Aug 23;97:82-91. doi: 10.1016/j.oraloncology.2019.08.004. [Epub ahead of print]

PMID:
31450171
6.

A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy.

Zini EM, Lanzola G, Quaglini S, Bossi P, Licitra L, Resteghini C.

Int J Med Inform. 2019 Sep;129:404-412. doi: 10.1016/j.ijmedinf.2019.06.004. Epub 2019 Jul 24.

PMID:
31445284
7.

Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.

Saba NF, Blumenschein G Jr, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P.

Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3.

8.

Locally advanced epithelial sinonasal tumors: The impact of multimodal approach.

Orlandi E, Cavalieri S, Granata R, Nicolai P, Castelnuovo P, Piazza C, Schreiber A, Turri-Zanoni M, Quattrone P, Miceli R, Infante G, Sessa F, Facco C, Calareso G, Iacovelli NA, Mattavelli D, Paderno A, Resteghini C, Locati LD, Licitra L, Bossi P.

Laryngoscope. 2019 Aug 1. doi: 10.1002/lary.28202. [Epub ahead of print]

PMID:
31369156
9.

Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma.

Locati LD, Serafini MS, Iannò MF, Carenzo A, Orlandi E, Resteghin C, Cavalieri S, Bossi P, Canevari S, Licitra L, De Cecco L.

Cancers (Basel). 2019 Jul 26;11(8). pii: E1057. doi: 10.3390/cancers11081057.

10.

Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.

Locati LD, Cavalieri S, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini E, Quattrone P, Granata R, Galbiati D, Platini F, Orlandi E, Mariani L, Licitra L.

Head Neck. 2019 Oct;41(10):3670-3676. doi: 10.1002/hed.25891. Epub 2019 Jul 29.

PMID:
31355973
11.

Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer.

Dauzier E, Lacas B, Blanchard P, Le QT, Simon C, Wolf G, Janot F, Horiuchi M, Tobias JS, Moon J, Simes J, Deshmane V, Mazeron JJ, Mehta S, Zaktonik B, Tamura M, Moyal E, Licitra L, Fortpied C, Haffty BG, Ghi MG, Gregoire V, Harris J, Bourhis J, Aupérin A, Pignon JP; MACH-NC Collaborative Group.

Oral Oncol. 2019 Aug;95:106-114. doi: 10.1016/j.oraloncology.2019.06.001. Epub 2019 Jun 15.

PMID:
31345376
12.

Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression?

Orlandi E, Iacovelli NA, Cavallo A, Resteghini C, Gandola L, Licitra L, Bossi P.

Head Neck. 2019 Oct;41(10):3733-3735. doi: 10.1002/hed.25848. Epub 2019 Jul 17. No abstract available.

PMID:
31313409
13.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL.

J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.

14.

Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up.

Imbimbo M, Alfieri S, Botta L, Bergamini C, Gloghini A, Calareso G, Orlandi E, Iacovelli NA, Guzzo M, Granata R, Resteghini C, Locati L, Volpi CC, Licitra L, Bossi P.

Otolaryngol Head Neck Surg. 2019 Jul 9:194599819860808. doi: 10.1177/0194599819860808. [Epub ahead of print]

PMID:
31286827
15.

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL.

Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.

16.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.

Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.

PMID:
31239321
17.

The day after De-ESCALaTE and RTOG 1016 trials results.

Orlandi E, Licitra L.

Future Oncol. 2019 Jun;15(18):2069-2072. doi: 10.2217/fon-2019-0168. Epub 2019 Jun 26. No abstract available.

18.

PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents.

Cavalieri S, Perrone F, Milione M, Bianco A, Alfieri S, Locati LD, Bergamini C, Resteghini C, Galbiati D, Platini F, Licitra L, Bossi P.

Oncology. 2019;97(2):112-118. doi: 10.1159/000500246. Epub 2019 May 21.

PMID:
31112973
19.

Identification of potentially druggable molecular alterations in skin adnexal malignancies.

Cavalieri S, Busico A, Capone I, Conca E, Dallera E, Quattrone P, Licitra L, Pruneri G, Bossi P, Perrone F.

J Dermatol. 2019 Jun;46(6):507-514. doi: 10.1111/1346-8138.14889. Epub 2019 Apr 30.

PMID:
31038235
20.

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).

Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D.

J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.

21.

Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?

Cavalieri S, Platini F, Bergamini C, Resteghini C, Galbiati D, Bossi P, Perrone F, Tamborini E, Quattrone P, Licitra L, Locati LD, Alfieri S.

Expert Opin Investig Drugs. 2019 May;28(5):435-443. doi: 10.1080/13543784.2019.1598376. Epub 2019 Apr 4. Review.

PMID:
30897975
22.

A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes.

De Cecco L, Serafini MS, Facco C, Granata R, Orlandi E, Fallai C, Licitra L, Marchesi E, Perrone F, Pilotti S, Quattrone P, Piazza C, Sessa F, Turri-Zanoni M, Battaglia P, Castelnuovo P, Antognoni P, Canevari S, Bossi P.

Oral Oncol. 2019 Mar;90:94-101. doi: 10.1016/j.oraloncology.2019.02.003. Epub 2019 Feb 11.

23.

Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.

van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, Cavalieri S, Tooten S, Bos E, Quattrone P, Verhaegh GW, Schalken JA, Licitra L, van Herpen CML; PALGA Group.

Eur J Cancer. 2019 Mar;110:62-70. doi: 10.1016/j.ejca.2018.12.035. Epub 2019 Feb 13.

PMID:
30771738
24.

Prevalence of Fatigue in Head and Neck Cancer Survivors.

Bossi P, Di Pede P, Guglielmo M, Granata R, Alfieri S, Iacovelli NA, Orlandi E, Guzzo M, Bianchi R, Ferella L, Infante G, Miceli R, Licitra L, Ripamonti CI.

Ann Otol Rhinol Laryngol. 2019 May;128(5):413-419. doi: 10.1177/0003489419826138. Epub 2019 Jan 30.

PMID:
30700107
25.

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.

Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Yim YM, Dimier N, Fittipaldo A, Basset-Séguin N, Hauschild A.

Eur J Dermatol. 2018 Dec 1;28(6):775-783. doi: 10.1684/ejd.2018.3448.

PMID:
30698147
26.

Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck.

Mirabile A, Miceli R, Calderone RG, Locati L, Bossi P, Bergamini C, Granata R, Perrone F, Mariani L, Licitra L.

Head Neck. 2019 Jun;41(6):1895-1902. doi: 10.1002/hed.25636. Epub 2019 Jan 16.

PMID:
30652392
27.

International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV.

Singer S, Amdal CD, Hammerlid E, Tomaszewska IM, Castro Silva J, Mehanna H, Santos M, Inhestern J, Brannan C, Yarom N, Fullerton A, Pinto M, Arraras JI, Kiyota N, Bonomo P, Sherman AC, Baumann I, Galalae R, Fernandez Gonzalez L, Nicolatou-Galitis O, Abdel-Hafeez Z, Raber-Durlacher J, Schmalz C, Zotti P, Boehm A, Hofmeister D, Krejovic Trivic S, Loo S, Chie WC, Bjordal K, Brokstad Herlofson B, Grégoire V, Licitra L; EORTC Quality of Life and the EORTC Head and Neck Cancer Groups.

Head Neck. 2019 Jun;41(6):1725-1737. doi: 10.1002/hed.25609. Epub 2019 Jan 12.

PMID:
30636188
28.

Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy.

Alessi A, Lorenzoni A, Cavallo A, Padovano B, Iacovelli NA, Bossi P, Alfieri S, Serafini G, Colombo CB, Cicchetti A, Mira M, Licitra L, Fallai C, Crippa F, Orlandi E.

Radiol Med. 2019 May;124(5):414-421. doi: 10.1007/s11547-018-0980-6. Epub 2018 Dec 17.

PMID:
30560502
29.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators.

Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Erratum in: Lancet. 2019 Jan 12;393(10167):132.

PMID:
30509740
30.

Data Set for the Reporting of Carcinomas of the Nasal Cavity and Paranasal Sinuses: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting.

Franchi A, Bishop JA, Coleman H, Flucke U, Licitra LF, Pendás JLL, Stelow EB, Toner M, Weinreb I, Wenig BM, Thompson LDR.

Arch Pathol Lab Med. 2019 Apr;143(4):424-431. doi: 10.5858/arpa.2018-0404-SA. Epub 2018 Nov 30.

PMID:
30500298
31.

Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials.

Bossi P, Miceli R, Benasso M, Corvò R, Bacigalupo A, Sanguineti G, Fallai C, Merlano MC, Infante G, Dani C, Di Giannantonio V, Licitra L.

Head Neck. 2018 Dec;40(12):2648-2656. doi: 10.1002/hed.25389. Epub 2018 Nov 17.

PMID:
30447127
32.

Use of apparent diffusion coefficient images to predict response to induction chemotherapy in sinonasal cancer.

Bologna M, Montin E, Corino VDA, Bossi P, Calareso G, Licitra L, Mainardi LT.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:782-785. doi: 10.1109/EMBC.2018.8512306.

PMID:
30440511
33.

Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients.

Orlandi E, Iacovelli NA, Rancati T, Cicchetti A, Bossi P, Pignoli E, Bergamini C, Licitra L, Fallai C, Valdagni R, Cavallo A.

Oral Oncol. 2018 Nov;86:266-272. doi: 10.1016/j.oraloncology.2018.10.006. Epub 2018 Oct 11.

PMID:
30409311
34.

Big Data in Head and Neck Cancer.

Resteghini C, Trama A, Borgonovi E, Hosni H, Corrao G, Orlandi E, Calareso G, De Cecco L, Piazza C, Mainardi L, Licitra L.

Curr Treat Options Oncol. 2018 Oct 25;19(12):62. doi: 10.1007/s11864-018-0585-2. Review.

PMID:
30361937
35.

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.

Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, Caballero C, Fortpied C, Bogaerts J, Govaerts AS, Staelens D, Raveloarivahy T, Rodegher L, Laes JF, Saada-Bouzid E, Machiels JP.

Ann Oncol. 2018 Dec 1;29(12):2313-2327. doi: 10.1093/annonc/mdy452.

36.

In Reply to Fakhry et al.

Bossi P, Miceli R, Granata R, Naimo S, Infante G, Locati LD, Iacovelli NA, Fallai C, Orlandi E, Licitra L.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):670-671. doi: 10.1016/j.ijrobp.2018.06.019. No abstract available.

PMID:
30238903
37.

Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group position paper based on the EORTC 1420 'Best of' and 24954 'larynx preservation' study.

Simon C, Caballero C, Gregoire V, Thurnher D, Koivunen P, Ceruse P, Spriano G, Nicolai P, Licitra L, Machiels JP, Hamoir M, Andry G, Mehanna H, Hunter KD, Dietz A, René Leemans C.

Eur J Cancer. 2018 Nov;103:69-77. doi: 10.1016/j.ejca.2018.07.140. Epub 2018 Sep 11. Review.

PMID:
30216847
38.

Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide.

Merlano MC, Merlotti AM, Licitra L, Denaro N, Fea E, Galizia D, Di Maio M, Fruttero C, Curcio P, Vecchio S, Russi EG, Corvò R.

Clin Transl Radiat Oncol. 2018 Aug 13;12:47-52. doi: 10.1016/j.ctro.2018.08.001. eCollection 2018 Aug.

39.

Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

Capdevila J, Newbold K, Licitra L, Popovtzer A, Moreso F, Zamorano J, Kreissl M, Aller J, Grande E.

Cancer Treat Rev. 2018 Sep;69:164-176. doi: 10.1016/j.ctrv.2018.06.019. Epub 2018 Jul 2. Review.

PMID:
30032061
40.

Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer.

Orlandi E, Miceli R, Infante G, Mirabile A, Alterio D, Cossu Rocca M, Denaro N, Vigna-Taglianti R, Merlotti A, Schindler A, Pizzorni N, Fallai C, Licitra L, Bossi P.

Dysphagia. 2019 Feb;34(1):52-62. doi: 10.1007/s00455-018-9913-8. Epub 2018 Jun 8.

PMID:
29948260
41.

Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial.

Siano M, Espeli V, Mach N, Bossi P, Licitra L, Ghielmini M, Frattini M, Canevari S, De Cecco L.

Oral Oncol. 2018 Jul;82:144-151. doi: 10.1016/j.oraloncology.2018.05.013. Epub 2018 May 28.

PMID:
29909889
42.

Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells.

Cappelletti V, Miodini P, Reduzzi C, Alfieri S, Daidone MG, Licitra L, Locati LD.

Ann Oncol. 2018 Jul 1;29(7):1598-1600. doi: 10.1093/annonc/mdy141. No abstract available.

43.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

44.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

45.

Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.

Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P.

Eur J Cancer. 2018 Jul;97:7-15. doi: 10.1016/j.ejca.2018.04.004. Epub 2018 May 4.

PMID:
29734047
46.

Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers.

Resteghini C, Perrone F, Miceli R, Bergamini C, Alfieri S, Orlandi E, Guzzo M, Granata R, Galbiati D, Cavalieri S, Locati L, Licitra L, Bossi P.

Tumori. 2018 Jun;104(3):213-220. doi: 10.1177/0300891618765558. Epub 2018 Apr 18.

PMID:
29714670
47.

Lenvatinib-induced renal failure: two first-time case reports and review of literature.

Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):379-385. doi: 10.1080/17425255.2018.1461839. Epub 2018 Apr 13. Review.

48.

Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.

Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P.

Cancer Treat Rev. 2018 Apr;65:78-86. doi: 10.1016/j.ctrv.2018.03.003. Epub 2018 Mar 20. Review.

PMID:
29574334
49.

Different View on Larynx Preservation Evidence-Based Treatment Recommendations.

Licitra L, Bonomo P, Sanguineti G, Bacigalupo A, Baldi GG, Valerini S, Bruzzi P.

J Clin Oncol. 2018 May 1;36(13):1376-1377. doi: 10.1200/JCO.2018.77.8001. Epub 2018 Mar 20. No abstract available.

PMID:
29558275
50.

Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.

Soulières D, Licitra L, Mesía R, Remenár É, Li SH, Karpenko A, Chol M, Wang YA, Solovieff N, Bourdeau L, Sellami D, Faivre S.

Clin Cancer Res. 2018 Jun 1;24(11):2505-2516. doi: 10.1158/1078-0432.CCR-17-2644. Epub 2018 Feb 28.

Supplemental Content

Loading ...
Support Center